Pathogenesis and Treatment of Extranodal Natural Killer/T-Cell Lymphoma

Seminars in Hematology

Volumn 51, Issue 1, 2014, Pages 42-51

  Suzuki, Ritsuro ^a  

^a NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ASPARAGINASE; B LYMPHOCYTE INDUCED MATURATION PROTEIN 1; CARBOPLATIN; CISPLATIN; CORTICOSTEROID; DEXAMETHASONE; ETOPOSIDE; IFOSFAMIDE; METHOTREXATE; MULTIDRUG RESISTANCE PROTEIN; TRANSCRIPTION FACTOR FKHRL1; VIRUS DNA;

AGGRESSIVE NK CELL LEUKEMIA; ARTICLE; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CARCINOGENESIS; CHROMOSOME 6; CHROMOSOME ABERRATION; DRUG EFFICACY; ENTEROPATHY ASSOCIATED T CELL LYMPHOMA; EPSTEIN BARR VIRUS; FOXO3 GENE; GENE DOSAGE; GENE MUTATION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; LYMPHOCYTOSIS; LYMPHOMA CELL; MULTIPLE CYCLE TREATMENT; NK T CELL LYMPHOMA; OVERALL SURVIVAL; PATIENT CARE; PHASE 2 CLINICAL TRIAL (TOPIC); PRDM1 GENE; PREDICTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; TAKEUCHI DISEASE; TREATMENT OUTCOME; TREATMENT RESPONSE; TUMOR SUPPRESSOR GENE; TUMOR VOLUME; WATCHFUL WAITING;

ANTINEOPLASTIC AGENTS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LYMPHOMA, EXTRANODAL NK-T-CELL; NEOPLASM STAGING; PROGNOSIS; RECURRENCE;

EID: 84892881790     PISSN: 00371963     EISSN: 15328686     Source Type: Journal    
DOI: 10.1053/j.seminhematol.2013.11.007     Document Type: Article

References (82)

1. Oshimi K. Progress in understanding and managing natural killer-cell malignancies. Br J Haematol 2007, 139:532-544.
2. Chan JKC, Quintanilla-Martinez L, Ferry JA, Peh S-C. Extranodal NK/T-cell lymphoma, nasal type. WHO classification of tumours of haematopoietic and lymphoid tissues. Lyon, France: IARC 2008, 285-288. S.H. Swerdlow, E. Campo, N.L. Harris (Eds.).
3. Chim C-S, Ma S-Y, Au W-Y, et al. Primary nasal natural killer cell lymphoma: long-term treatment outcome and relationship with the International Prognostic Index. Blood 2004, 103:216-221.
4. Lee J, Suh C., Park Y.H., et al. Extranodal natural killer T-cell lymphoma, nasal-type: a prognostic model from a retrospective multicenter study. J Clin Oncol 2006, 24:612-618.
5. Suzuki R, Suzumiya J, Yamaguchi M, et al. Prognostic factors for mature natural killer (NK)-cell neoplasms: aggressive NK-cell leukemia and extranodal NK-cell lymphoma, nasal-type. Ann Oncol 2010, 21:1032-1040.
6. Au WY, Weisenburger DD, Intragumtornchai T, et al. Clinical differences between nasal and extranasal NK/T-cell lymphoma: a study of 136 cases from the International Peripheral T-cell Lymphoma Project. Blood 2009, 113:3931-3937.
7. Yamaguchi M, Kita K, Miwa H, et al. Frequent expression of P-glycoprotein/MDR1 by nasal T-cell lymphoma cells. Cancer 1995, 76:2351-2356.
8. Egashira M, Kawamata N, Sugimoto K, Oshimi K. P-glycoprotein expression on normal and abnormally expanded natural killer cells and inhibition of P-glycoprotein function by cyclosporin A and its analogue, PSC833. Blood 1999, 93:599-606.
9. Trambas C, Wang Z, Cianfriglia M, Woods G. Evidence that natural killer cells express mini P-glycoproteins but not classic 170 kDa P-glycoprotein. Br J Haematol 2001, 114:177-184.
10. Kim WS, Song SY, Ahn YC, et al. CHOP followed by involved field radiation: is it optimal for localized nasal natural killer/T-cell lymphomaα. Ann Oncol 2001, 12:349-352.
11. Kim SJ, Kim WS. Treatment of localized extranodal NK/T cell lymphoma, nasal type. Int J Hematol 2010, 92:690-696.
12. Suzuki R. Treatment of advanced extranodal NK/T cell lymphoma, nasal-type and aggressive NK-cell leukemia. Int J Hematol 2010, 92:697-701.
13. Wong KF, Chan JK, Kwong YL. Identification of del(6)(q21q25) as a recurring chromosomal abnormality in putative NK cell lymphoma/leukaemia. Br J Haematol 1997, 98:922-926.
14. Tien HF, Su IJ, Tang JL, et al. Clonal chromosomal abnormalities as direct evidence for clonality in nasal T/natural killer cell lymphomas. Br J Haematol 1997, 97:621-625.
15. Siu LL, Wong KF, Chan JK, Kwong YL. Comparative genomic hybridization analysis of natural killer cell lymphoma/leukemia. Recognition of consistent patterns of genetic alterations. Am J Pathol 1999, 155:1419-1425.
16. Nakashima Y, Tagawa H, Suzuki R, et al. Genome-wide array-based comparative genomic hybridization of natural killer cell lymphoma/leukemia: different genomic alteration patterns of aggressive NK-cell leukemia and extranodal NK/T-cell lymphoma, nasal type. Genes Chromosomes Cancer 2005, 44:247-255.
17. Iqbal J, Kucuk C, Deleeuw RJ, et al. Genomic analyses reveal global functional alterations that promote tumor growth and novel tumor suppressor genes in natural killer-cell malignancies. Leukemia 2009, 23:1139-1151.
18. Berti E, Recalcati S, Girgenti V, Fanoni D, Venegoni L, Vezzoli P. Cutaneous extranodal NK/T-cell lymphoma: a clinicopathologic study of 5 patients with array-based comparative genomic hybridization. Blood 2010, 116:165-170.
19. Karube K, Nakagawa M, Tsuzuki S, et al. Identification of FOXO3 and PRDM1 as tumor-suppressor gene candidates in NK-cell neoplasms by genomic and functional analyses. Blood 2011, 118:3195-3204.
20. Pasqualucci L, Compagno M, Houldsworth J, et al. Inactivation of the PRDM1/BLIMP1 gene in diffuse large B cell lymphoma. J Exp Med 2006, 203:311-317.
21. Tam W, Gomez M, Chadburn A, Lee JW, Chan WC, Knowles DM. Mutational analysis of PRDM1 indicates a tumor-suppressor role in diffuse large B-cell lymphomas. Blood 2006, 107:4090-4100.
22. Küçük C, Iqbal J, Hu X, et al. PRDM1 is a tumor suppressor gene in natural killer cell malignancies. Proc Natl Acad Sci USA 2011, 108:20119-20124.
23. Suzuki R. Leukemia and lymphoma of natural killer cells. J Clin Exp Hematopathol 2005, 45:51-70.
24. Suzuki R, Takeuchi K, Ohshima K, Nakamura S. Extranodal NK/T-cell lymphoma: diagnosis and treatment cues. Hematol Oncol 2008, 26:66-72.
25. Kawa K. Epstein-Barr virus-associated diseases in humans. Int J Hematol 2000, 71:108-117.
26. Jaffe ES, Chan JKC, Su I-J, et al. Report of the Workshop on Nasal and Related Extranodal Angiocentric T/Natural Killer Cell Lymphomas. Definitions, differential diagnosis, and epidemiology. Am J Surg Pathol 1996, 20:103-111.
27. Suzumiya J, Takeshita M, Kimura N, et al. Expression of adult and fetal natural killer cell markers in sinonasal lymphomas. Blood 1994, 83:2255-2260.
28. + T-cell receptor silent peripheral T-cell lymphomas are natural killer cell lymphomas. Blood 1996, 87:1466-1473.
29. Ohshima K, Suzumiya J, Shimazaki K, et al. Nasal T/NK cell lymphomas commonly express perforin and Fas ligand: important mediators of tissue damage. Histopathology 1997, 31:444-450.
30. Mori N, Yatabe Y, Oka K, et al. Expression of perforin in nasal lymphoma. Am J Pathol 1996, 149:699-705.
31. Kim TM, Park YH, Lee SY, et al. Local tumor invasiveness is more predictive of survival than International Prognostic Index in stage I(E)/II(E) extranodal NK/T-cell lymphoma, nasal type. Blood 2005, 106:3785-3790.
32. Li YX, Coucke PA, Li JY, et al. Primary non-Hodgkin's lymphoma of the nasal cavity: prognostic significance of paranasal extension and the role of radiotherapy and chemotherapy. Cancer 1998, 83:449-456.
33. Li CC, Tien HF, Tang JL, et al. Treatment outcome and pattern of failure in 77 patients with sinonasal natural killer/T-cell or T-cell lymphoma. Cancer 2004, 100:366-375.
34. Ng SB, Lai KW, Murugaya S, et al. Nasal-type extranodal natural killer/T-cell lymphomas: a clinicopathologic and genotypic study of 42 cases in Singapore. Mod Pathol 2004, 17:1097-1107.
35. Cuadra-Garcia I, Proulx GM, Wu CL, et al. Sinonasal lymphoma: a clinicopathologic analysis of 58 cases from the Massachusetts General Hospital. Am J Surg Pathol 1999, 23:1356-1369.
36. Aviles A, Diaz NR, Neri N, Cleto S, Talavera A. Angiocentric nasal T/natural killer cell lymphoma: a single centre study of prognostic factors in 108 patients. Clin Lab Haematol 2000, 22:215-220.
37. Barrionuevo C, Zaharia M, Martinez MT, et al. Extranodal NK/T-cell lymphoma, nasal type: study of clinicopathologic and prognosis factors in a series of 78 cases from Peru. Appl Immunohistochem Mol Morphol 2007, 15:38-44.
38. Gualco G, Domeny-Duarte P, Chioato L, Barber G, Natkunam Y, Bacchi CE. Clinicopathologic and molecular features of 122 Brazilian cases of nodal and extranodal NK/T-cell lymphoma, nasal type, with EBV subtyping analysis. Am J Surg Pathol 2011, 35:1195-1203.
39. Chauchet A, Michallet AS, Berger F, et al. Complete remission after first-line radio-chemotherapy as predictor of survival in extranodal NK/T cell lymphoma. J Hematol Oncol 2012, 5:27.
40. Pongpruttipan T, Sukpanichnant S, Assanasen T, et al. Extranodal NK/T-cell lymphoma, nasal type, includes cases of natural killer cell and αβ, γδ, and αβ/γδ T-cell origin: a comprehensive clinicopathologic and phenotypic study. Am J Surg Pathol 2012, 36:481-499.
41. Suzuki R, Suzumiya J, Oshimi K. Differences between nasal and extra-nasal NK/T-cell lymphoma. Blood 2009, 113:6260-6261.
42. Campo E, Swerdlow SH, Harris NL, Pileri S, Stein H, Jaffe ES. The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications. Blood 2011, 117:5019-5032.
43. Cheung MMC, Chan JKC, Lau WH, et al. Primary non-Hodgkin's lymphoma of the nose and nasopharynx: clinical features, tumor immunophenotype, and treatment outcome in 113 patients. J Clin Oncol 1998, 16:70-77.
44. Kim GE, Cho JH, Yang WI, et al. Angiocentric lymphoma of the head and neck: patterns of systemic failure after radiation treatment. J Clin Oncol 2000, 18:54-63.
45. You JY, Chi KH, Yang MH, et al. Radiation therapy versus chemotherapy as initial treatment for localized nasal natural killer (NK)/T-cell lymphoma: a single institute survey in Taiwan. Ann Oncol 2004, 15:618-625.
46. Kim SJ, Kim BS, Choi CW, et al. Treatment outcome of front-line systemic chemotherapy for localized extranodal NK/T cell lymphoma in nasal and upper aerodigestive tract. Leuk Lymphoma 2006, 47:1265-1273.
47. Li YX, Yao B, Jin J, et al. Radiotherapy as primary treatment for stage IE and IIE nasal natural killer/T-cell lymphoma. J Clin Oncol 2006, 24:181-189.
48. Yamaguchi M, Tobinai K, Oguchi M, et al. Phase I/II study of concurrent chemoradiotherapy for localized nasal natural killer/T-cell lymphoma: Japan Clinical Oncology Group Study JCOG0211. J Clin Oncol 2009, 27:5594-5600.
49. Kim SJ, Kim K, Kim BS, et al. Phase II trial of concurrent radiation and weekly cisplatin followed by VIPD chemotherapy in newly diagnosed, stage IE to IIE, nasal, extranodal NK/T-cell lymphoma: Consortium for Improving Survival of Lymphoma Study. J Clin Oncol 2009, 27:6027-6032.
50. Yamaguchi M, Tobinai K, Oguchi M, et al. Concurrent chemoradiotherapy for localized nasal natural killer/T-cell lymphoma: an updated analysis of the Japan clinical oncology group study JCOG0211. J Clin Oncol 2012, 30:4044-4046.
51. Nagafuji K, Fujisaki T, Arima F, Ohshima K. L-asparaginase induced durable remission of relapsed nasal NK/T-cell lymphoma after autologous peripheral blood stem cell transplantation. Int J Hematol 2001, 74:447-450.
52. Obama K, Tara M, Niina K. L-asparaginase-based induction therapy for advanced extranodal NK/T-cell lymphoma. Int J Hematol 2003, 78:248-250.
53. Matsumoto Y, Nomura K, Kanda-Akano Y, et al. Successful treatment with Erwinia L-asparaginase for recurrent natural killer/T cell lymphoma. Leuk Lymphoma 2003, 44:879-882.
54. Ando M, Sugimoto K, Kitoh T, et al. Selective apoptosis of natural killer-cell tumours by l-asparaginase. Br J Haematol 2005, 130:860-868.
55. Yamaguchi M, Suzuki R, Kwong YL, et al. Phase I study of dexamethasone, methotrexate, ifosfamide, l-asparaginase, and etoposide (SMILE) chemotherapy for advanced-stage, relapsed or refractory extranodal natural killer (NK)/T-cell lymphoma and leukemia. Cancer Sci 2008, 99:1016-1020.
56. Yamaguchi M, Kwong YL, Kim WS, et al. Phase II study of SMILE chemotherapy for newly-diagnosed stage IV, relapsed or refractory extranodal NK/T-cell lymphoma, nasal type: the NK-Cell Tumor Study Group (NKTSG) study. J Clin Oncol 2011, 29:4410-4416.
57. Suzuki R, Kwong Y, Maeda Y, et al. Long-term follow-up of the phase II study of SMILE chemotherapy for patients with newly diagnosed stage IV, relapsed or refractory extranodal NK/T-cell lymphoma, nasal type: the NK-cell Tumor Study Group study. Hematol Oncol 2013, 31 suppl. S1:175. [abstract 235].
58. Jaccard A, Petit B, Girault S, et al. l-Asparaginase-based treatment of 15 western patients with extranodal NK/T-cell lymphoma and leukemia and a review of the literature. Ann Oncol 2009, 20:110-116.
59. Jaccard A, Gachard N, Marin B, et al. Efficacy of l-asparaginase with methotrexate and dexamethasone (AspaMetDex regimen) in patients with refractory or relapsing extranodal NK/T-cell lymphoma, a phase II study. Blood 2011, 117:1834-1839.
60. Jaccard A, Suerez F, Delmer A, et al. A prospective phase II trial of an L-asparaginase containing regimen in extranodal NK/T-cell lymphoma. Hematol Oncol 2013, 31 suppl S1:129. [abstract 099].
61. Au WY, Lie AK, Liang R, et al. Autologous stem cell transplantation for nasal NK/T-cell lymphoma: a progress report on its value. Ann Oncol 2003, 14:1673-1676.
62. Suzuki R, Suzumiya J, Nakamura S, et al. Hematopoietic stem cell transplantation for natural killer-cell lineage neoplasms. Bone Marrow Transplant 2006, 37:425-431.
63. Kim HJ, Bang SM, Lee J, et al. High-dose chemotherapy with autologous stem cell transplantation in extranodal NK/T-cell lymphoma: a retrospective comparison with non-transplantation cases. Bone Marrow Transplant 2006, 37:819-824.
64. Lee J, Au WY, Park MJ, et al. Autologous hematopoietic stem cell transplantation in extranodal NK/T-cell lymphoma: a multinational, multicenter, matched controlled study. Biol Blood Marrow Transplant 2008, 14:1356-1364.
65. Murashige N, Kami M, Kishi Y, et al. Allogeneic haematopoietic stem cell transplantation as a promising treatment for natural killer-cell neoplasms. Br J Haematol 2005, 130:561-567.
66. Suzuki R, Kako S, Hyo R, et al. Comparison of autologous and allogeneic hematopoietic stem cell transplantation for extranodal NK/T-cell lymphoma, nasal-type: analysis of the Japan Society for Hematopoietic Cell Transplantation (JSHCT) Lymphoma Working Group. Blood 2011, 118:503. [abstract 503].
67. Hammerschmidt W, Sugden B. Genetic analysis of immortalizing functions of Epstein-Barr virus in human B lymphocytes. Nature 1989, 340:393-397.
68. Dennis Lo YM, Chan WY, Ng EKW, et al. Circulating Epstein-Barr virus DNA in the serum of patients with gastric carcinoma. Clin Cancer Res 2001, 7:1856-1859.
69. Chan KCA, Zhang J, Chan ATC, et al. Molecular characterization of circulating EBV DNA in the plasma of nasopharyngeal carcinoma and lymphoma patients. Cancer Res 2003, 63:2028-2032.
70. Au WY, Pang A, Choy C, Chim CS, Kwong YL. Quantification of circulating Epstein-Barr virus (EBV) DNA in the diagnosis and monitoring of natural killer cell and EBV-positive lymphomas in immunocompetent patients. Blood 2004, 104:243-249.
71. Suzuki R, Yamaguchi M, Izutsu K, et al. Prospective measurement of Epstein-Barr virus-DNA in plasma and peripheral blood mononuclear cells of extranodal NK/T-cell lymphoma, nasal type. Blood 2011, 118:6018-6022.
72. Ito Y, Kimura H, Maeda Y, et al. Pretreatment EBV-DNA copy number is predictive of response and toxicities to SMILE chemotherapy for extranodal NK/T-cell lymphoma, nasal type. Clin Cancer Res 2012, 18:4183-4190.
73. Kimura H, Ito Y, Suzuki R, Nishiyama Y. Measuring Epstein-Barr virus (EBV) load: its significance and application in each EBV-associated disease. Rev Med Virol 2008, 18:305-319.
74. Suzuki R, Suzumiya J, Nakamura S, et al. Aggressive natural killer (NK)-cell leukemia revisited: large granular lymphocyte leukemia of cytotoxic NK cells. Leukemia 2004, 18:763-770.
75. Ishida F, Ko YH, Kim WS, et al. Aggressive natural killer cell leukemia: therapeutic potential of L-asparaginase and allogeneic hematopoietic stem cell transplantation. Cancer Sci 2012, 103:1079-1083.
76. Caligiuri MA. Human natural killer cells. Blood 2008, 112:461-469.
77. Takahashi H, Sakai R, Hattori Y, et al. Successful disease control with l-asparaginase monotherapy for aggressive natural killer cell leukemia with severe hepatic failure. Leuk Lymphoma 2013, 54:662-664.
78. Vega F, Chang CC, Schwartz MR, et al. Atypical NK-cell proliferation of the gastrointestinal tract in a patient with antigliadin antibodies but not celiac disease. Am J Surg Pathol 2006, 30:539-544.
79. Takeuchi K, Yokoyama M, Ishizawa S, et al. Lymphomatoid gastropathy: a distinct clinicopathologic entity of self-limited pseudomalignant NK-cell proliferation. Blood 2010, 116:5631-5637.
80. Mansoor A, Pittaluga S, Beck PL, Wilson WH, Ferry JA, Jaffe ES. NK-cell enteropathy: a benign NK-cell lymphoproliferative disease mimicking intestinal lymphoma: clinicopathologic features and follow-up in a unique case series. Blood 2011, 117:1447-1452.
81. Tefferi A, Li C-Y, Witzig TE, Dhodapkar MV, Okuno SH, Phyliky RL. Chronic natural killer cell lymphocytosis: a descriptive clinical study. Blood 1994, 84:2721-2725.
82. Loughran TP, Zambello R, Ashley R, et al. Failure to detect Epstein-Barr virus DNA in peripheral blood mononuclear cells of most patients with large granular lymphocyte leukemia. Blood 1993, 81:2723-2727.